MDAN-21

MDAN-21 is a bivalent opioid ligand that contains both μ-opioid receptor agonists and δ-opioid receptor antagonists. MDAN-21 has a strong analgesic effect and does not produce tolerance in mouse studies. MDAN-21 can effectively inhibit the withdrawal of morphine dependent monkeys and alleviate abnormal pain in the study of rhesus monkeys. MDAN-21 can be used for the study of allodynia[1].

Product Specifications

CAS Number

873573-64-9

UNSPSC

12352005

Target

Opioid Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

O[C@]12[C@]34[C@](OC5=C(O)C=CC(C[C@@]2([H])N(CC4)CC6CC6)=C53)([H])C7=C(C8=CC=CC(NC(COCC(NCCCCCCCNC(COCC(N[C@@H]9[C@@]%10([H])[C@]%11%12C%13=C(C[C@](N(CC%12)C)([H])[C@@]%11(CC9)O)C=CC(O)=C%13O%10)=O)=O)=O)=O)=C8N7)C1

Molecular Formula

C58H71N7O12

Molecular Weight

1058.22

References & Citations

[1]Aceto MD, et al. MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys. Int J Med Chem. 2012;2012:327257.